...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The Urologic clinics of North America >Allogeneic stem cell transplantation as immunotherapy for renal cell carcinoma: from immune enhancement to immune replacement.
【24h】

Allogeneic stem cell transplantation as immunotherapy for renal cell carcinoma: from immune enhancement to immune replacement.

机译：同种异体干细胞移植作为肾细胞癌的免疫疗法：从免疫增强到免疫替代。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The lack of efficacy of chemotherapeutics, radiotherapy, and cytokine-based immunotherapy has catalyzed the preliminary enthusiasm for nonmyeloablative stem cell transplants as a novel investigational tool for treating metastatic RCC. The observation that cytokine-refractory metastatic RCC may regress following allogeneic transplantation attests to the powerful nature of the graft-versus-tumor effect that results from this treatment modality. Pilot trials and recent in vitro data provide the first clear evidence that the graft-versus-tumor effect mounted against RCC can produce clinically meaningful regression of a metastatic solid tumor. Given this observation, the authors have begun to expand the investigational use of nonmyeloablative stem cell transplants to other treatment-refractory genitourinary tumors, including metastatic bladder and prostate cancer. It is hoped that future demonstrations of graft-versus-tumor effects in other solid malignancies will lay the groundwork for the development of tumor-targeted strategies that use allogeneic transplantation of donor lymphocytes as an immunotherapeutic platform. Further advances in systemic and selective immunosuppressive agents that limit acute GVHD hold the potential to decrease the toxicity associated with nonmyeloablative stem cell transplants and may ultimately broaden the clinical applicability of this approach.
机译：化学疗法，放射疗法和基于细胞因子的免疫疗法缺乏疗效，已经催化了非清髓性干细胞移植作为治疗转移性RCC的新型研究工具的初步热情。同种异体移植后，细胞因子难治性转移性RCC可能消退的观察证明，这种治疗方式导致了移植物抗肿瘤效应的强大作用。初步试验和最新的体外数据提供了第一个明确的证据，表明针对RCC的移植物抗肿瘤作用可以产生转移性实体瘤的临床意义。鉴于这一观察结果，作者已开始将非清髓性干细胞移植的研究用途扩展到其他治疗难治性泌尿生殖系统肿瘤，包括转移性膀胱癌和前列腺癌。希望将来在其他实体恶性肿瘤中表现出移植物抗肿瘤作用将为开发靶向肿瘤的策略奠定基础，该策略将同种异体供体淋巴细胞移植用作免疫治疗平台。限制急性GVHD的全身性和选择性免疫抑制剂的进一步发展具有降低与非清髓性干细胞移植相关的毒性的潜力，并可能最终扩大该方法的临床适用性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号